Ants swept away 26 trillion at the beginning of the year… Samsung Electronics·SK Biopharm Green Light Issue

Since the beginning of the year, ants (individual investors) have been advancing. In the new year, it swept 2.6 trillion won in two trading days. About half of these are Samsung Electronics(82,900 +0.85%)And SK Biopharm(158,500 -0.63%)I also shopped for over 300 billion won. Yeouido Securities Street has good prospects for both stocks.

Ant, stock shopping from the beginning of the year

According to the Korea Exchange on the 6th, the amount of net purchases made by individuals on the domestic stock market over the last two days on the 4th and 5th was estimated at 2,613.5 billion won. This is in contrast to the sales of 2,281.7 billion won for institutions and 3372 billion won for foreigners.

As the environment of low interest rates and low growth continues, it is analyzed that funds are flowing into the stock market with high expected returns.

According to the financial sector, the balance of deposits and savings in December of last year at five major banks, including Shinhan National, Woori Hana Nonghyup, was 673 trillion 728.6 billion won, a decrease of 7,583.2 billion won from the previous month. Excluding the decrease compared to the previous month in June of last year (10,1690 billion won), it has decreased the most in a year.

Investor deposits also showed an increase. According to the Financial Investment Association, the investor’s deposit in December last year was KRW 65,522.7 billion, an increase of 3,935 billion KRW from the previous month (61,5876 billion KRW). Investor deposits are money that securities companies receive and store temporarily from investors, and are usually considered as stock market funds.

Kang Song-cheol, a researcher at Shinhan Financial Investment, said, “Individual investors continued their record net purchases last year and established themselves as the dominant power of the stock market.” Judged.

The stock that ants have focused on buying since the beginning of the year is Samsung Electronics, the leading stock market in Korea. Samsung Electronics, which they bought during the two trading days, was 1.281.6 billion won. Considering the amount of Samsung Electronics purchased for a month in December of last year was 2,265 trillion won, this is a considerable level.

The share price of Samsung Electronics has been soaring recently. At the beginning of the second half of last year (July 1), the stock price, which was only 52,600 won, settled at around 60,000 won in November, and then rose sharply in December, reaching 80,000 won over 70,000 won. At the beginning of this year, it rose to the 83,000 won range.

The previous day, it rose to 83,900 won, but as of the previous day, the market cap of Samsung Electronics increased to 50,864.7 billion won. It is the first time in history that the market cap has exceeded 500 trillion won based on the closing price.

A stock market came out with a target price that exceeded KRW 110,000, as a target price of KRW 100,000 was insufficient. Hana Financial Investment raised the target price of Samsung Electronics from 86,000 won to 111,000 won.

Kim Kyung-min, a researcher at this securities firm, emphasized that “the possibility of increasing dividends, shortage of foundry supply and rising product prices (inflation), and the effect of a turnaround in the DRAM industry will have a positive effect on the share price.”

The second most popular item for ants is SK Biopharm. Until the day before, the ants had bought 34.2 billion won worth. As the stock price plunged due to supply-demand effects, it is interpreted that the ants started to buy net.

On the 4th, 492,063 shares of SK Biopharm stocks held by institutional investors were released to the market after the six-month mandatory holding period. This is more than 37% of the 13.2 million shares allocated by institutions at the time of the public offering of SK Biopharm.

Previously, 13 million shares were released 15 days after listing, 262,500 shares a month later, and 1.7 million shares last October, which is far higher than the previous release.

On the 4th, when institutional stocks were released, the stock price of SK Biopharm closed at 154500 won, down 14,500 won (8.58%) from the previous day. However, the previous day, as low-priced purchases flowed from the plunge, it ended at 16,500 won, up 6,000 won (3.88%).

The outlook for SK Biopharm is bright. Han Byeong-hwa, a researcher at Eugene Investment & Securities, diagnosed that “Senovamate’s global success potential has increased, with the success of exporting technology to leading Japanese epilepsy drug companies, and increasing number of technology exporting countries in Europe.”

However, one researcher believes that the fact that the share price rise after listing is larger than expected is a burden. SK Biopharm’s share price still exceeds the public offering price of 49,000 won. As of the previous day, SK Biopharm completed the transaction for 16,500 won, which is 227% of the public offering price.

Lee Song-ryul, reporter of Hankyung.com [email protected]